GO:0061772 xenobiotic transport across blood-nerve barrier: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061772 describes the directed movement of a xenobiotic through the blood-nerve barrier, a process that controls drug and toxin access to peripheral nerves.
• The blood-nerve barrier is formed by perineurial cells and endoneurial microvascular endothelial cells, which together create a selective interface for xenobiotic transport.
• Transport across this barrier involves multiple routes, including paracellular diffusion and carrier-mediated transcellular pathways, and is influenced by physicochemical properties of the xenobiotic.
• Dysfunction or modulation of blood-nerve barrier transport is relevant to chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and nerve-targeted drug delivery.
• Key genes and proteins implicated in barrier function and xenobiotic handling include ABCB1 (P-glycoprotein), ABCC1, ABCG2, SLC transporters, and tight junction components such as TJP1 and OCLN.
• CRISPR-based knockout, knock-in, and overexpression models enable causal testing of candidate genes in blood-nerve barrier transport and are supported by EDITGENE services.
Description
The blood-nerve barrier (BNB) is a specialized interface that protects peripheral nerves from circulating xenobiotics, including drugs, toxins, and environmental chemicals. GO:0061772, xenobiotic transport across blood-nerve barrier, is defined as the directed movement of a xenobiotic through this barrier. This process is critical for understanding how therapeutic agents reach peripheral nerves and why some neurotoxic compounds accumulate in nerve tissue. Researchers studying neuropharmacology, toxicology, and peripheral neuropathy require precise models to dissect the molecular players that mediate or restrict xenobiotic flux across the BNB. The term encompasses both passive and active transport mechanisms, and its regulation directly impacts drug efficacy and safety in the peripheral nervous system.
xenobiotic transport across blood-nerve barrier At A Glance
| GO ID | GO:0061772 |
|---|---|
| GO term | xenobiotic transport across blood-nerve barrier |
| Ontology | biological_process |
| Synonym | drug transport across blood-nerve barrier; drug transport across perineurial barrier |
| Definition | The directed movement of a xenobiotic through the blood-nerve barrier. |
| Major function | Regulates entry of drugs, toxins, and environmental chemicals into peripheral nerve tissue. |
| Related barriers | Blood-brain barrier (BBB) and blood-nerve barrier (BNB) share transport mechanisms but differ in cellular composition. |
| Key cell types | Perineurial cells, endoneurial endothelial cells, and Schwann cells contribute to barrier properties. |
| Research relevance | Target for improving drug delivery to peripheral nerves and understanding chemotherapy-induced neurotoxicity. |
What Is GO:0061772?
GO:0061772, xenobiotic transport across blood-nerve barrier, refers to the directed movement of a foreign chemical substance (xenobiotic) through the blood-nerve barrier. This biological process includes the translocation of drugs, toxins, or other exogenous compounds from the bloodstream into or across the perineurial and endoneurial barriers that isolate peripheral nerve fibers. It is synonymous with drug transport across blood-nerve barrier and drug transport across perineurial barrier. The process is essential for determining the pharmacokinetics and neurotoxicity of systemically administered agents.
Why Is xenobiotic transport across blood-nerve barrier Important in Cell Biology?
Understanding xenobiotic transport across the blood-nerve barrier is essential for predicting drug distribution to peripheral nerves, designing neuroprotective strategies, and interpreting neurotoxicity data. The BNB restricts the entry of many systemically administered compounds, limiting the efficacy of treatments for peripheral neuropathies and nerve injuries. Conversely, barrier dysfunction can permit neurotoxic xenobiotics to accumulate, contributing to chemotherapy-induced peripheral neuropathy and other nerve damage. Therefore, GO:0061772 is a focal point for translational research in neuropharmacology, toxicology, and drug delivery.
• Determines the bioavailability of drugs intended to treat peripheral nerve disorders.
• Protects peripheral nerves from circulating neurotoxins and environmental chemicals.
• Modulates the efficacy and toxicity of chemotherapeutic agents that cause peripheral neuropathy.
• Influences the development of nerve-targeted nanomedicines and prodrugs.
• Provides a model for comparative studies with the blood-brain barrier.
• Involves active efflux transporters that can be targeted to enhance drug penetration.
• Relevant to diabetic neuropathy, where barrier dysfunction may exacerbate nerve damage.
• Key to understanding species differences in drug-induced neurotoxicity.
• Supports the development of in vitro BNB models for high-throughput screening.
• Guides CRISPR-based validation of candidate transporters and tight junction proteins.
What Happens During xenobiotic transport across blood-nerve barrier?
Xenobiotic encounter with the perineurial barrier
In simple terms: A drug or toxin in the blood first meets the outer layer of the nerve barrier.
The perineurium, composed of tight junction-coupled perineurial cells, forms the outermost diffusion barrier of the blood-nerve barrier. Xenobiotics must traverse this layer to reach the endoneurial space. Transport can occur via paracellular routes when tight junctions are disrupted, or via transcellular pathways involving transporters and vesicular mechanisms. The physicochemical properties of the xenobiotic, such as lipophilicity and molecular size, influence which route predominates.
Endoneurial endothelial cell interface
In simple terms: Inside the nerve, blood vessels have a second barrier that controls what enters the nerve tissue.
Endoneurial microvessels are lined by endothelial cells that form a blood-nerve barrier analogous to the blood-brain barrier. These cells express tight junction proteins and efflux transporters that restrict xenobiotic entry. Carrier-mediated transport systems, including members of the ABC and SLC families, actively pump xenobiotics out of endothelial cells or facilitate their uptake. The coordinated action of these transporters determines the net flux of xenobiotics into the endoneurial compartment.
Transcellular transport and efflux mechanisms
In simple terms: Some chemicals are carried through cells by transporter proteins, while others are pumped back out.
Transcellular transport across the blood-nerve barrier involves solute carrier (SLC) transporters that mediate uptake into cells, followed by efflux via ATP-binding cassette (ABC) transporters such as ABCB1 (P-glycoprotein) and ABCG2. These transporters can create a functional barrier by actively extruding xenobiotics back into the bloodstream. The balance between uptake and efflux determines whether a xenobiotic accumulates in nerve tissue or is excluded.
Paracellular diffusion and tight junction regulation
In simple terms: When the seals between cells loosen, chemicals can slip between them.
Tight junctions between perineurial cells and endothelial cells limit paracellular diffusion of xenobiotics. Proteins such as claudins, occludin, and zonula occludens-1 (TJP1) form the junctional complex. Modulation of tight junction integrity by cytokines, growth factors, or pharmacological agents can alter barrier permeability and thus xenobiotic transport. This route is particularly important for small hydrophilic compounds that cannot easily cross cell membranes.
Intracellular trafficking and metabolism
In simple terms: Once inside barrier cells, chemicals may be modified or moved to other compartments.
After entering perineurial or endothelial cells, xenobiotics may undergo metabolic transformation by phase I and phase II enzymes, altering their transport properties. Vesicular trafficking and endosomal pathways can also contribute to transcytosis of macromolecular xenobiotics. These intracellular processes add another layer of regulation to GO:0061772 and can be studied using tracer molecules and imaging.
Key Genes Involved in GO:0061772 xenobiotic transport across blood-nerve barrier
The following genes and proteins are experimentally implicated in blood-nerve barrier function, xenobiotic transport, or related barrier mechanisms, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ABCB1 | Efflux transporter (P-glycoprotein) at barrier interfaces | Limits xenobiotic entry into nerve; target for enhancing drug delivery |
| ABCC1 | Multidrug resistance-associated protein efflux | Contributes to barrier function and neuroprotection |
| ABCG2 | ATP-binding cassette efflux transporter | Modulates drug penetration across blood-nerve barrier |
| SLC2A1 | Glucose transporter, facilitative diffusion | Marker of barrier endothelial cells; potential transport route |
| SLC7A5 | L-type amino acid transporter | Mediates uptake of large neutral amino acids and drugs |
| TJP1 | Tight junction scaffolding protein (ZO-1) | Regulates paracellular permeability |
| OCLN | Tight junction protein occludin | Maintains barrier integrity |
| CLDN5 | Claudin-5, tight junction protein | Key determinant of paracellular seal |
| CLDN1 | Claudin-1, tight junction protein | Expressed in perineurium; regulates permeability |
| CDH5 | VE-cadherin, endothelial adherens junction | Supports barrier integrity |
| PECAM1 | Platelet endothelial cell adhesion molecule | Endothelial marker; involved in leukocyte transmigration |
| VIM | Vimentin, intermediate filament | Cytoskeletal support in perineurial cells |
| LAMA2 | Laminin subunit alpha-2 | Basement membrane component of nerve barrier |
| COL4A1 | Collagen type IV alpha-1 | Basement membrane structural protein |
| AGRN | Agrin, heparan sulfate proteoglycan | Contributes to barrier matrix |
| S100B | Schwann cell marker | Indirectly reflects nerve barrier status |
| MPZ | Myelin protein zero | Peripheral nerve myelin; barrier-associated |
| PMP22 | Peripheral myelin protein 22 | Involved in hereditary neuropathies with barrier defects |
How Is xenobiotic transport across blood-nerve barrier Regulated?
The transport of xenobiotics across the blood-nerve barrier is regulated at multiple levels. Tight junction assembly and disassembly are controlled by signaling pathways including protein kinase C and Rho GTPases. Efflux transporter expression can be induced by xenobiotic-activated nuclear receptors such as PXR and CAR, altering barrier permeability. Inflammatory cytokines, including TNF-alpha and IL-1beta, can disrupt barrier integrity and increase paracellular transport. Additionally, growth factors like VEGF modulate endothelial permeability. These regulatory mechanisms are potential targets for modulating drug delivery to peripheral nerves.
xenobiotic transport across blood-nerve barrier and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABCB1 | Chemotherapy-induced peripheral neuropathy | Knockout and overexpression in endothelial/perineurial cells |
| TJP1 | Diabetic neuropathy, barrier dysfunction | Point mutation to disrupt tight junction binding |
| PMP22 | Charcot-Marie-Tooth disease type 1A | Knock-in of patient mutations in Schwann cells |
| CLDN5 | Barrier permeability in neuroinflammation | Knockout in endothelial cells |
| SLC7A5 | Drug delivery to peripheral nerves | Overexpression for uptake studies |
Chemotherapy-induced peripheral neuropathy
Many chemotherapeutic agents, such as vincristine and paclitaxel, cause peripheral neuropathy partly due to their interaction with blood-nerve barrier transport. Efflux transporters like ABCB1 can limit drug entry, but when overwhelmed or inhibited, neurotoxic concentrations may accumulate in nerves. Understanding GO:0061772 is therefore critical for predicting and mitigating chemotherapy-induced neurotoxicity.
Diabetic neuropathy
Diabetes alters blood-nerve barrier permeability, potentially allowing neurotoxic metabolites and xenobiotics to enter peripheral nerves. Hyperglycemia-induced oxidative stress and inflammation can disrupt tight junctions and transporter function. This barrier dysfunction may contribute to the progression of diabetic peripheral neuropathy.
Inherited neuropathies
Mutations in genes encoding myelin and barrier-associated proteins, such as PMP22 and MPZ, can compromise blood-nerve barrier integrity. In Charcot-Marie-Tooth disease, barrier defects may exacerbate nerve damage by permitting xenobiotic entry. Studying GO:0061772 in these contexts can reveal new therapeutic targets.
Neurotoxicology and environmental exposure
Environmental neurotoxins, including heavy metals and industrial solvents, can cross the blood-nerve barrier and cause peripheral nerve damage. The transport mechanisms defined by GO:0061772 determine susceptibility to these agents. Research in this area informs risk assessment and regulatory decisions.
From xenobiotic transport across blood-nerve barrier-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ABCB1 limit xenobiotic entry into peripheral nerve? | ABCB1 knockout in endothelial cells or whole-body KO |
| Does a point mutation in TJP1 alter paracellular permeability? | CRISPR point mutation knock-in in perineurial cells |
| Can a tagged transporter be used to track localization? | Knock-in of fluorescent tag on SLC7A5 |
| Does overexpression of ABCG2 enhance barrier function? | Overexpression in blood-nerve barrier cell lines |
| Which genes are essential for barrier formation? | CRISPR library screening in co-culture models |
| Can a disease-associated mutation in PMP22 disrupt barrier? | Knock-in of PMP22 mutation in Schwann cells |
How to Study the xenobiotic transport across blood-nerve barrier Process
| Method | What It Measures | Typical Application |
|---|---|---|
| TEER measurement | Barrier tightness | Assessing integrity of in vitro BNB models |
| Fluorescent tracer permeability | Paracellular and transcellular flux | Screening xenobiotic transport |
| LC-MS/MS quantification | Concentration of xenobiotics in nerve tissue | Pharmacokinetic studies |
| Immunofluorescence | Localization of transporters and junction proteins | Validating CRISPR knockouts |
| RNA-seq | Gene expression changes | Identifying regulators of barrier function |
| CRISPR library screening | Essential genes for barrier transport | High-throughput discovery |
| Intravital microscopy | Real-time barrier permeability | In vivo validation |
| Western blot | Protein expression levels | Confirming knockout/overexpression |
In vitro blood-nerve barrier models
Co-culture systems of perineurial cells and endothelial cells on transwell inserts allow measurement of transepithelial/transendothelial electrical resistance (TEER) and permeability to fluorescent tracers. These models can be genetically modified using CRISPR to test the role of specific genes in xenobiotic transport.
Transport assays with radiolabeled or fluorescent xenobiotics
Using radiolabeled drugs or fluorescent compounds, researchers can quantify flux across barrier models and calculate permeability coefficients. Efflux ratios can be determined by comparing transport in the presence and absence of transporter inhibitors.
Imaging and tracer studies in vivo
Intravital microscopy and fluorescent tracer injection in animal models allow real-time assessment of blood-nerve barrier permeability. These techniques can be combined with genetic knockouts to identify transport pathways.
Transcriptomic and proteomic profiling
RNA-seq and mass spectrometry-based proteomics of isolated barrier cells can reveal expression of transporters, tight junction proteins, and regulatory factors. Comparing wild-type and CRISPR-edited cells identifies genes that modulate xenobiotic transport.
How CRISPR Can Be Used to Study GO:0061772 xenobiotic transport across blood-nerve barrier
Knockout
CRISPR knockout of candidate genes such as ABCB1 or TJP1 in blood-nerve barrier cell models can reveal their contribution to xenobiotic transport. Knockout endothelial cells or perineurial cells are generated by introducing indels in early exons, followed by functional transport assays.
Point Mutation
Point mutations can be introduced to model disease-associated variants or to disrupt specific functional domains of transporters and junction proteins. For example, mutating phosphorylation sites in TJP1 can test their role in barrier regulation.
Knock-in
Knock-in of fluorescent tags or reporter genes allows tracking of transporter localization and dynamics in live cells. This approach is useful for studying trafficking of ABC transporters under different conditions.
Overexpression
Overexpression of efflux transporters like ABCG2 or uptake transporters like SLC7A5 can enhance or reduce xenobiotic permeability, providing gain-of-function evidence. Stable overexpression cell lines are valuable for drug screening.
How EDITGENE Supports xenobiotic transport across blood-nerve barrier Research
Researchers studying xenobiotic transport across blood-nerve barrier-related genes often need to determine whether a candidate gene is causally involved in barrier function or drug permeability. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell and animal models, enabling rigorous testing of gene function in the context of GO:0061772.
Contact EDITGENE today to design your custom CRISPR model for xenobiotic transport across blood-nerve barrier research.
Frequently Asked Questions About xenobiotic transport across blood-nerve barrier
What is GO:0061772?
GO:0061772 is the Gene Ontology term for xenobiotic transport across blood-nerve barrier, defined as the directed movement of a xenobiotic through the blood-nerve barrier.
What genes are involved in xenobiotic transport across blood-nerve barrier?
Key genes include ABCB1, ABCC1, ABCG2, SLC7A5, TJP1, OCLN, and CLDN5, among others.
How is xenobiotic transport across blood-nerve barrier studied?
It is studied using in vitro barrier models, transport assays, imaging, and CRISPR-based genetic editing.
Why is the blood-nerve barrier important for drug delivery?
The blood-nerve barrier restricts drug entry into peripheral nerves, affecting treatment efficacy for neuropathies.
What diseases are associated with blood-nerve barrier dysfunction?
Chemotherapy-induced peripheral neuropathy, diabetic neuropathy, and inherited neuropathies are associated with barrier dysfunction.
Can CRISPR be used to study blood-nerve barrier transport?
Yes, CRISPR knockout, knock-in, and overexpression models enable causal testing of genes involved in xenobiotic transport.
What are the synonyms for GO:0061772?
Synonyms include drug transport across blood-nerve barrier and drug transport across perineurial barrier.
Which transporters mediate xenobiotic efflux at the blood-nerve barrier?
ABCB1 (P-glycoprotein), ABCC1, and ABCG2 are major efflux transporters at the blood-nerve barrier.
How does the blood-nerve barrier differ from the blood-brain barrier?
Both are selective barriers, but the blood-nerve barrier involves perineurial cells and endoneurial endothelial cells, while the blood-brain barrier is primarily endothelial.
What model systems are available for studying GO:0061772?
In vitro co-culture models, primary cells, and CRISPR-edited cell lines are commonly used.
Conclusion
GO:0061772, xenobiotic transport across blood-nerve barrier, is a critical biological process that governs the access of drugs and toxins to peripheral nerves. Understanding its molecular mechanisms, key genes, and regulatory pathways is essential for developing effective therapies for peripheral neuropathies and for predicting neurotoxicity. CRISPR-based models and advanced screening technologies offer powerful tools to dissect this process and identify new targets for modulating barrier function.
References
- 1. Erdő F et al.. 2018. Evaluation of intranasal delivery route of drug administration for brain targeting.. Brain Res Bull 143:155-170 PMID: 30449731
- 2. Saunders NR et al.. 2016. The biological significance of brain barrier mechanisms: help or hindrance in drug delivery to the central nervous system?. F1000Res 5 PMID: 26998242
- 3. Tachikawa M et al.. 2013. [Multi-disciplinary research approaches on the brain barrier transport system, a dynamic interface].. Brain Nerve 65(2):121-36 PMID: 23399670
